To further assess the impact of CD56 on NK cell identification in lung tumors, we sorted tumor infiltrated cells into CD45- (not leukocyte cells) and CD45+ CD3- and with flow cytometry we analyzed the canonical CD16/CD56 combination, the CD122/CD94 (KLRD1/IL2RB) new marker pair or solely CD56. The gene discussed is NCAM1; the disease is neoplasm.